This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

1:1 initial unit dosing - available in the SoloStar pen, cartridges and vials1*

*When transferring from other insulin products, dose adjustment of Trurapi® or basal insulin may be needed. Insulin aspart has a faster onset and shorter duration of action than soluble human insulin. Close glucose monitoring during transfer and initial weeks is recommended.1

    EU, European Union; FAQ, frequently asked questions; NHS, National Health Service; PD, pharmacodynamic; PK, pharmacokinetic; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; UK, United Kingdom.


    1. Trurapi SmPC (April 2023)
    2. NHS DM+M: REF-161114. Available at: Date accessed: April 2023
    3. Kapitza C, et al. Diabetes Technol Ther. 2020;22(4):278–284.
    4. Garg SK, et al. Diabetes Technol Ther. 2020;22(2):85–95.

Diabetes Stories

Watch peer-to-peer videos of payors and healthcare professionals sharing best practices of adopting a rapid acting insulin biosimilar.
Some of these videos are related to HCPs sharing their experiences with a different rapid acting insulin biosimilar.

Start and Switch

Watch and download resources to support your rapid acting insulin adoption.

How have your colleagues implemented Biosimilar insulins?

Get insights through personalised peer-to-peer interactions from across the country.

MAT-XU-2201545 (v3.0)
Date of Preparation: February 2023

MAT-XU-2205461 (v6.0) 
Date of Preparation: April 2023